Details for New Drug Application (NDA): 085771
✉ Email this page to a colleague
NDA 085771 describes HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, which is a drug marketed by Watson Labs and is included in one NDA. Additional details are available on the HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE profile page.
The generic ingredient in HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
The generic ingredient in HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for 085771
| Tradename: | HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE |
| Applicant: | Watson Labs |
| Ingredient: | hydralazine hydrochloride; hydrochlorothiazide; reserpine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;15MG;0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
